DMSO (dimethyl sulfoxide) does have antifungal activity against Candida species in laboratory settings, but it is not an approved or established treatment for Candida infections. At concentrations of 10%, DMSO nearly eliminates Candida growth in lab cultures, while concentrations between 2.5% and 7.5% show a dose-dependent inhibitory effect. Below 1.25%, it has little meaningful impact. These are promising numbers from petri dishes, not from clinical trials in humans.
How DMSO Affects Candida Cells
DMSO disrupts Candida through its interaction with cell membranes. It has a strong affinity for the outer layer of the cell’s lipid membrane, and when it binds there, it disorganizes the lipid structure and makes the membrane more permeable. Think of it like loosening the mortar between bricks: the wall still stands, but it leaks. At higher concentrations, this damage is severe enough to kill the cell outright, as observed in closely related yeast species.
Beyond membrane disruption, DMSO interferes with Candida’s internal metabolism in multiple ways. Research published in the Journal of Fungi found that DMSO altered 13 different metabolic pathways in Candida albicans biofilms. It specifically suppresses fatty acid production, which the fungus needs to build and maintain its cell structures. It also increases oxidative stress inside the cell and appears to interfere with the cell’s energy production cycle by boosting levels of a compound that blocks key steps in cellular respiration. The net effect is a fungal cell that can’t build new membranes, can’t produce energy efficiently, and is under increasing internal chemical stress.
Effects on Germ Tubes and Biofilms
One of the ways Candida albicans becomes dangerous is by forming germ tubes, elongated structures that help the yeast invade tissue and transition into a more aggressive form. DMSO at concentrations of 2.5% to 7.5% inhibits germ tube formation in a dose-dependent manner. At 10%, germ tube growth is nearly negligible. This matters because blocking this transition could theoretically limit how deeply Candida penetrates tissue.
Candida also protects itself by forming biofilms, sticky communities of cells that are notoriously resistant to antifungal drugs. The metabolic disruption DMSO causes in biofilm cells suggests it could weaken these protective structures, though this has only been demonstrated in controlled lab environments.
Specific Concentrations That Inhibit Growth
The numbers from laboratory studies paint a fairly clear picture:
- Below 1.25%: No significant effect on Candida growth compared to untreated controls.
- 2.5%: Statistically significant growth inhibition in Candida glabrata, enough that researchers flag this concentration as no longer “neutral” in drug testing.
- 2.5% to 7.5%: A roughly linear dose-response relationship, with higher concentrations producing more inhibition of both Candida albicans and related fungi.
- 10%: 100% growth inhibition of Candida glabrata in one study. Near-complete suppression of germ tube formation in Candida albicans in another.
These concentrations refer to the percentage of DMSO in a liquid growth medium in a lab. Translating these numbers to what would happen on or inside the human body is not straightforward.
DMSO as a Drug Delivery Vehicle
Where DMSO may be most practically relevant for fungal infections is not as a standalone antifungal, but as a penetration enhancer. DMSO is well known for its ability to carry other molecules through skin and tissue barriers that would otherwise block them. In one reported case of stubborn toenail fungus (onychomycosis), a combination of a low-dose antiseptic with DMSO as the delivery vehicle was able to penetrate the nail and reach the infection underneath, something most topical antifungals fail to do.
This penetration ability is why DMSO appears frequently in antifungal research. When scientists test drugs like fluconazole in the lab, they often dissolve the drug in DMSO. A study of 145 clinical Candida strains confirmed that dissolving standard antifungals in DMSO instead of water did not change their potency, with 99% agreement between the two solvents. DMSO doesn’t boost or diminish the drugs it carries; it simply gets them where they need to go.
Why DMSO Isn’t a Candida Treatment
The only FDA-approved use of DMSO in humans is for a bladder condition called interstitial cystitis, administered directly into the bladder by a healthcare provider. Claims that DMSO effectively treats infections, arthritis, wounds, or other conditions have not been proven through the kind of rigorous clinical trials required for approval. No clinical trials have tested DMSO as a standalone Candida treatment in humans.
There is also the practical problem of concentration. The levels needed to significantly inhibit Candida (2.5% and above) overlap with levels that cause notable side effects on human tissue. A systematic review of adverse reactions found that topical DMSO commonly causes skin scaling or dryness (15% of patients), burning or stinging (16%), redness (9%), and itching (6%). These reactions follow a dose-response pattern: higher concentrations produce more side effects. At 10%, the concentration that wipes out Candida in a dish, skin reactions can be significant. Applying concentrations high enough to kill Candida could easily irritate or damage the tissue you’re trying to protect, particularly on sensitive mucous membranes where yeast infections commonly occur.
What This Means in Practice
DMSO has genuine antifungal properties against Candida. It disrupts membranes, shuts down fatty acid production, increases oxidative stress, and blocks germ tube formation. These are real biological effects confirmed in multiple laboratory studies. But laboratory antifungal activity and clinical usefulness are two very different things. Many substances kill Candida in a dish, including bleach and rubbing alcohol, without being appropriate treatments for human infections.
If you’re dealing with a Candida infection, proven antifungal medications remain the standard of care. Where DMSO could eventually play a role is as a delivery system, helping existing antifungals reach infections in hard-to-penetrate areas like nails or deep tissue. That application is closer to how researchers and clinicians already use DMSO, carrying other drugs rather than acting as the drug itself.